JP2012501332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501332A5 JP2012501332A5 JP2011525134A JP2011525134A JP2012501332A5 JP 2012501332 A5 JP2012501332 A5 JP 2012501332A5 JP 2011525134 A JP2011525134 A JP 2011525134A JP 2011525134 A JP2011525134 A JP 2011525134A JP 2012501332 A5 JP2012501332 A5 JP 2012501332A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- lyophilized
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9232608P | 2008-08-27 | 2008-08-27 | |
| US61/092,326 | 2008-08-27 | ||
| PCT/US2009/054842 WO2010027766A1 (en) | 2008-08-27 | 2009-08-25 | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015184258A Division JP2016028086A (ja) | 2008-08-27 | 2015-09-17 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012501332A JP2012501332A (ja) | 2012-01-19 |
| JP2012501332A5 true JP2012501332A5 (https=) | 2012-10-04 |
| JP5931442B2 JP5931442B2 (ja) | 2016-06-08 |
Family
ID=41495339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011525134A Active JP5931442B2 (ja) | 2008-08-27 | 2009-08-25 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
| JP2015184258A Pending JP2016028086A (ja) | 2008-08-27 | 2015-09-17 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015184258A Pending JP2016028086A (ja) | 2008-08-27 | 2015-09-17 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8263748B2 (https=) |
| EP (1) | EP2331078B1 (https=) |
| JP (2) | JP5931442B2 (https=) |
| CN (1) | CN102202655B (https=) |
| AU (1) | AU2009288419B2 (https=) |
| CA (1) | CA2734919C (https=) |
| MX (1) | MX2011002159A (https=) |
| WO (1) | WO2010027766A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| WO2012009760A1 (en) * | 2010-07-20 | 2012-01-26 | Cephalon Australia Pty Ltd | Anti-il-23 heterodimer specific antibodies |
| MX2019000046A (es) | 2010-11-04 | 2023-10-05 | Boehringer Ingelheim Int | Anticuerpos anti-il-23. |
| CN107233569B (zh) | 2011-10-25 | 2021-08-31 | 普罗西纳生物科学有限公司 | 抗体制剂和方法 |
| EP2798077A2 (en) | 2011-12-31 | 2014-11-05 | Allergan, Inc. | Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A |
| JP6345123B2 (ja) * | 2012-02-16 | 2018-06-20 | サンタラス， インコーポレイテッド | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
| PL3326649T3 (pl) | 2012-05-03 | 2022-04-25 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23p19 |
| CZ304514B6 (cs) | 2012-11-23 | 2014-06-11 | Biotechnologický Ústav Av Čr, V.V.I. | Polypeptidy pro léčbu autoimunitních chorob založenou na blokaci receptoru pro lidský cytokin IL-23 |
| UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| SG11201507483PA (en) | 2013-03-15 | 2015-10-29 | Amgen Inc | Methods for treating crohn's disease using an anti-il23 antibody |
| SG11201507482UA (en) | 2013-03-15 | 2015-10-29 | Amgen Inc | Methods for treating psoriasis using an anti-il-23 antibody |
| EP3708679A1 (en) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| EA202193002A2 (ru) | 2014-09-03 | 2022-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединение, нацеленное на ил-23a и фно-альфа, и его применение |
| AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| AU2016215535B2 (en) | 2015-02-04 | 2021-09-16 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
| CN108290058B (zh) | 2015-09-17 | 2023-05-16 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| EP3371225A2 (en) | 2015-11-04 | 2018-09-12 | AstraZeneca AB | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
| US11220541B2 (en) | 2015-12-22 | 2022-01-11 | Amgen Inc. | CCL20 as a predictor of clinical response to IL23-antagonists |
| EP3405400B1 (en) | 2016-01-22 | 2020-02-19 | Baxter International Inc. | Method and machine for producing sterile solution product bags |
| DK3405161T3 (da) | 2016-01-22 | 2020-02-03 | Baxter Int | Sterilopløsningsproduktpose |
| AU2017386888B2 (en) | 2016-12-28 | 2024-08-08 | Jcr Pharmaceuticals Co., Ltd. | Lyophilized preparation |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN112689643A (zh) | 2018-07-13 | 2021-04-20 | 阿斯特捷利康合作创业有限责任公司 | 用布雷库单抗治疗溃疡性结肠炎 |
| WO2020081408A1 (en) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| KR20210096559A (ko) | 2018-11-27 | 2021-08-05 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 항IL-23p19 항체 및 이의 용도 |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| CA3143604A1 (en) * | 2019-04-15 | 2020-10-22 | Sun Pharmaceutical Industries Limited | Methods for treatment of subjects with psoriatic arthritis |
| TW202535466A (zh) * | 2019-09-09 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| GB202107153D0 (en) | 2021-05-19 | 2021-06-30 | UCB Biopharma SRL | Method for filling vials containing liquid drug products |
| CN115785267B (zh) * | 2021-09-10 | 2023-12-15 | 三优生物医药(上海)有限公司 | 一种靶向IL-23p19的抗体或其抗原结合片段及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6991790B1 (en) * | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| DK1820516T3 (da) * | 1999-02-22 | 2013-10-28 | Univ Connecticut | Nye albuminfrie faktor VIII-præparater |
| MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| DK2236154T3 (en) | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
| CN1816356A (zh) * | 2003-05-14 | 2006-08-09 | 免疫原公司 | 药物缀合物组合物 |
| EP1688432B1 (en) * | 2003-10-09 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Igm high concentration stabilized solution |
| NZ564098A (en) * | 2005-06-15 | 2010-04-30 | Schering Corp | Anti-IGF1R antibody formulations |
| SI2452694T1 (sl) * | 2005-06-30 | 2019-05-31 | Janssen Biotech, Inc. | Protitelesa proti-IL-23, sestavki in postopki uporabe |
| DE602006015830D1 (de) | 2005-08-25 | 2010-09-09 | Lilly Co Eli | Anti-il-23-antikörper |
| PT1931710T (pt) | 2005-08-31 | 2017-03-28 | Merck Sharp & Dohme | Anticorpos anti-il-23 manipulados |
| HUE034269T2 (en) | 2005-12-29 | 2018-02-28 | Janssen Biotech Inc | Human anti-IL-23 antibodies, preparations, methods and applications |
| JP2009532336A (ja) * | 2006-03-06 | 2009-09-10 | メディミューン，エルエルシー | ヒト化抗ｃｄ２２抗体、並びに腫瘍、移植及び自己免疫疾患の治療におけるこれらの使用 |
| US7790862B2 (en) | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
| KR20090100461A (ko) * | 2007-01-16 | 2009-09-23 | 아보트 러보러터리즈 | 건선의 치료방법 |
| ES2708988T3 (es) | 2007-02-23 | 2019-04-12 | Merck Sharp & Dohme | Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética |
| JP2010518858A (ja) | 2007-02-23 | 2010-06-03 | シェーリング コーポレイション | 操作された抗−ｉｌ−２３ｐ１９抗体 |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
-
2009
- 2009-08-25 EP EP09791868A patent/EP2331078B1/en active Active
- 2009-08-25 CA CA2734919A patent/CA2734919C/en active Active
- 2009-08-25 MX MX2011002159A patent/MX2011002159A/es active IP Right Grant
- 2009-08-25 AU AU2009288419A patent/AU2009288419B2/en active Active
- 2009-08-25 JP JP2011525134A patent/JP5931442B2/ja active Active
- 2009-08-25 US US13/061,076 patent/US8263748B2/en active Active
- 2009-08-25 WO PCT/US2009/054842 patent/WO2010027766A1/en not_active Ceased
- 2009-08-25 CN CN2009801428023A patent/CN102202655B/zh active Active
-
2015
- 2015-09-17 JP JP2015184258A patent/JP2016028086A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012501332A5 (https=) | ||
| JP7528249B2 (ja) | Ｃｏｖｉｄ－１９に対する抗原特異的免疫療法、融合タンパク質、およびその使用方法 | |
| Huleatt et al. | A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity | |
| Tai et al. | A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection | |
| Sun et al. | Thermal stability of self-assembled peptide vaccine materials | |
| US9861696B2 (en) | Monoclonal antibodies for Ebola and Marburg viruses | |
| JP5960120B2 (ja) | ウイルス粒子の安定化 | |
| US20230181730A1 (en) | Methods of treating infections | |
| BR112021004193A2 (pt) | vacinas pneumocócicas multivalentes | |
| JP2016534052A5 (https=) | ||
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| Nguyen et al. | The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents | |
| Stinson et al. | Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine | |
| US11406704B2 (en) | Adjuvants | |
| KR20130114210A (ko) | 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물 | |
| KR102922338B1 (ko) | 폐렴구균 융합 단백질 백신 | |
| JPS58213723A (ja) | 口蹄疫ウイルス抗原の特異性を有する小型ペプチド | |
| CN114729031A (zh) | 抗溶瘤病毒抗原抗体及其使用方法 | |
| Demircan et al. | Biotin functionalized self‐assembled peptide nanofiber as an adjuvant for immunomodulatory response | |
| TWI615158B (zh) | 多肽之調配物 | |
| US20230210980A1 (en) | Chimeric adenoviral vectors | |
| KR20230135598A (ko) | 안정한 코로나바이러스 단백질 및 그의 백신 조성물 | |
| US20230233667A1 (en) | Coronavirus vaccine | |
| Zagorski et al. | Peptide Nanoarray Scaffold Vaccine for SARS-COV-2 and Its Variants of Concerns | |
| US10829542B2 (en) | Methods for affecting Salmonella infections |